Status:
RECRUITING
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Stroke
Transient Ischemic Attack (TIA)
Eligibility:
All Genders
18-89 years
Phase:
NA
Brief Summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or hi...
Detailed Description
This is a pilot clinical trial for feasibility
Eligibility Criteria
Inclusion
- Patients 18-89 years of age
- admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
- eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)
Exclusion
- diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
- prescribed anticoagulation prior to stroke
- treated with intravenous thrombolysis
- treated with mechanical thrombectomy
- missing NIH Stroke Scale score
Key Trial Info
Start Date :
April 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2029
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06943586
Start Date
April 9 2025
End Date
April 1 2029
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233